Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β-Estradiol and Dydrogesterone

Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy.

OBJECTIVE To compare the effects of tibolone, estriol and conventional hormone replacement therapy (HRT) on mammographic parenchymal density in postmenopausal women. DESIGN AND SETTING This was a non-randomised, prospective, longitudinal, comparative study conducted at two specialist outpatient clinics in Chile. PATIENTS AND PARTICIPANTS 210 non-obese, postmenopausal women aged <65 years wi...

Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition

BACKGROUND It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer's disease (AD). OBJECTIVE To investigate the effects of hormone therapy on amyloid-β deposition in recently postmenopausal women. METHODS Participants within 5-36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-...

Postmenopausal hormone replacement therapy with Tibolone decreases serum lipoprotein(a).

Lipoprotein(a) is a cholesterol-rich plasma lipoprotein consisting of LDL and apolipoprotein(a). Apolipoprotein(a) shows structural similarity with plasminogen and thus may interfere with thrombogenesis. Lipoprotein(a) has been shown to be a strong independent risk factor for coronary heart disease. So far no drug or diet is known to have prominent effects on the serum levels of lipoprotein(a)....

Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.

Most available postmenopausal hormone replacement therapies (HRT) offer similar efficacy, but differ with respect to the cardiovascular risks associated with their use. There is a wealth of evidence to suggest that, unlike oral estrogens, transdermal estradiol does not increase the risk of venous thromboembolism, probably due to its lack of effect on the coagulation cascade, including thrombin ...

Transdermal 17beta-estradiol for preventing postmenopausal bone loss.